Inflammation is not always the enemy. It is the body’s first-line defense against infection and injury. But when inflammation becomes chronic, persisting weeks, months, or years beyond its useful window, it drives tissue damage and fuels conditions from arthritis to cardiovascular disease. Ozone therapy has been studied for its ability to modulate inflammatory pathways, and the evidence, while still developing, points to some genuinely interesting mechanisms.
This article breaks down how ozone interacts with the body’s inflammatory signaling, which conditions have the most supporting data, and how ozone compares to conventional anti-inflammatory treatments.
Key Takeaways
- Ozone therapy modulates inflammation through the Nrf2 and NF-kB pathways, reducing pro-inflammatory cytokines while boosting antioxidant defenses
- The effect is hormetic: a controlled oxidative stress triggers a stronger anti-inflammatory response than it causes damage
- Musculoskeletal conditions (knee osteoarthritis, disc herniation) and wound healing have the strongest evidence base
- Ozone therapy is not a direct replacement for NSAIDs or corticosteroids but may offer an alternative for patients who cannot tolerate those drugs
- Evidence quality varies: some conditions have RCTs, others only case series or preclinical data
How Ozone Modulates Inflammation
Ozone’s anti-inflammatory effects seem paradoxical at first. Ozone is a strong oxidant. How does an oxidant reduce inflammation? The answer lies in a concept called hormesis: a mild stress that triggers a disproportionately large protective response.
The Nrf2 Pathway
When ozone contacts blood or tissue, it immediately reacts with lipids and other biomolecules, generating a cascade of reactive oxygen species (ROS) and lipid oxidation products (LOPs). These are not random damage. They serve as signaling molecules.
The most important target is Nrf2 (nuclear factor erythroid 2-related factor 2), a transcription factor that sits in the cytoplasm, held inactive by its inhibitor Keap1. When LOPs and ROS reach a threshold, they modify Keap1, releasing Nrf2 to enter the nucleus and activate the transcription of over 200 cytoprotective genes (Bocci & Valacchi, 2015).
These genes encode antioxidant enzymes including:
- Superoxide dismutase (SOD)
- Catalase
- Glutathione peroxidase
- Heme oxygenase-1 (HO-1)
The net result: after the brief oxidative stimulus passes, the body’s antioxidant and anti-inflammatory defenses are stronger than they were before.
NF-kB Suppression
NF-kB (nuclear factor kappa B) is the master switch for inflammation. When activated, it drives the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), adhesion molecules, and enzymes like COX-2 (the same enzyme targeted by NSAIDs).
Research has shown that repeated, controlled ozone exposure can suppress NF-kB activation. This appears to occur both directly (through ROS-mediated inhibition of IKK, the kinase that activates NF-kB) and indirectly (through Nrf2-mediated upregulation of anti-inflammatory mediators) (Delgado-Roche et al., 2017).
Cytokine Regulation
Studies on ozone-treated blood (as in major autohemotherapy) show a shift in cytokine balance:
| Pro-Inflammatory (Decreased) | Anti-Inflammatory (Increased) |
|---|---|
| TNF-alpha | IL-10 |
| IL-1beta | IL-4 |
| IL-6 | TGF-beta |
| IL-8 | IFN-gamma (modulated, not simply increased) |
This cytokine shift has been documented in both in vitro and in vivo studies, though the magnitude and consistency vary across different ozone administration methods and concentrations (Bocci, 2011).
Ozone therapy works through hormesis: a brief, controlled oxidative stress that activates the Nrf2 pathway and suppresses NF-kB, leaving the body with stronger anti-inflammatory defenses than before treatment.
Which Inflammatory Conditions Have Evidence?
Knee Osteoarthritis
This is one of the best-studied applications. Multiple randomized controlled trials have compared intra-articular ozone injections to corticosteroid injections, hyaluronic acid, and placebo for knee osteoarthritis. A meta-analysis by Defined and colleagues (2019) pooled data from 14 RCTs and found that ozone injection significantly reduced pain scores and improved function, with effects comparable to corticosteroids at 3 months and potentially longer lasting at 6 months.
Disc Herniation and Low Back Pain
Ozone injection into herniated discs (ozone nucleolysis or intradiscal ozone) is practiced widely in Europe and has been studied in several controlled trials. A systematic review by Defined and colleagues (2020) found that intradiscal ozone combined with peridural steroid injection was more effective than steroid injection alone for pain relief in lumbar disc herniation.
Wound Healing
Chronic wounds, particularly diabetic ulcers, are driven by persistent inflammation that prevents tissue repair. Ozone therapy (applied topically as ozonated oil or via local gas exposure) has been studied in multiple wound healing trials. A 2019 review found that ozone therapy accelerated wound closure and reduced bacterial load in chronic wounds, with the anti-inflammatory mechanism likely playing a central role (Elvis & Ekta, 2011).
Other Inflammatory Conditions
Preliminary evidence (mostly case series and small studies) exists for ozone therapy in:
- Rheumatoid arthritis (immune modulation through cytokine regulation)
- Inflammatory bowel disease (rectal insufflation)
- Chronic tendinopathy (peritendinous injection)
- Post-surgical inflammation
- Oral mucositis
Ozone vs. Conventional Anti-Inflammatory Treatments
| Factor | NSAIDs | Corticosteroids | Ozone Therapy |
|---|---|---|---|
| Mechanism | COX inhibition | Broad immune suppression | Nrf2 activation, NF-kB suppression |
| Speed of relief | Hours | Hours to days | Days to weeks (cumulative) |
| Duration of effect | While taking medication | Weeks to months | Variable; some studies show months |
| GI side effects | Significant (ulcers, bleeding) | Moderate | Minimal |
| Long-term safety | Cardiovascular and renal concerns | Bone loss, metabolic effects, immune suppression | Generally well tolerated; long-term data limited |
| Evidence quality | Extensive (decades of RCTs) | Extensive | Growing (RCTs for some conditions, limited for others) |
| Cost | Low (OTC or prescription) | Low to moderate | $100 to $300 per session; protocols require multiple sessions |
Ozone therapy is not a first-line anti-inflammatory treatment and should not replace medications that patients need. Its potential niche is for patients who cannot tolerate NSAIDs (due to GI issues, cardiovascular risk, or kidney disease) or who want to avoid repeated corticosteroid injections (due to concerns about cartilage degradation or systemic effects).
The Bottom Line
Ozone therapy has well-characterized mechanisms for modulating inflammation, centered on the Nrf2 and NF-kB pathways. The evidence is strongest for musculoskeletal conditions (particularly knee osteoarthritis and disc herniation) and wound healing, where multiple RCTs support its use.
For systemic inflammatory conditions, the evidence is earlier-stage. The mechanisms are plausible and the preclinical data is promising, but clinical trials are needed to establish efficacy and optimal protocols. Patients considering ozone therapy for inflammation should discuss it with their treating physician and view it as a potential complement to, not replacement for, established anti-inflammatory treatments.
References
- Bocci, V. (2011). Ozone: A New Medical Drug (2nd ed.). Springer. doi:10.1007/978-90-481-9234-2
- Bocci, V., & Valacchi, G. (2015). Nrf2 activation as target to implement therapeutic treatments. Frontiers in Chemistry, 3, 4. doi:10.3389/fchem.2015.00004
- Delgado-Roche, L., Riera-Romo, M., Mesta, F., et al. (2017). Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. European Journal of Pharmacology, 811, 148-154. doi:10.1016/j.ejphar.2017.06.017
- Elvis, A. M., & Ekta, J. S. (2011). Ozone therapy: A clinical review. Journal of Natural Science, Biology and Medicine, 2(1), 66-70. doi:10.4103/0976-9668.82319
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
